Invivyd, Inc – Development of a Monoclonal Antibody for COVID-19 Prevention in Vulnerable Populations

Dave Hering, CEO of  Invivyd, Inc, a biopharmaceutical company discusses the development of a monoclonal antibody to prevent COVID-19 in immunocompromised people, through their pivotal Phase 3 trial called CANOPY.  This is the final step in a rapid development program for an antibody infusion to prevent symptomatic COVID-19 in vulnerable populations.

Dave Hering, M.B.A. has served as our Chief Executive Officer and a member of the Board of Directors since July 2022. He joined Invivyd in June 2021 and previously served as our Interim Chief Executive Officer and as our Chief Operating Officer. Prior to joining the Invivyd team, Dave held a variety of senior leadership roles in his six years at Pfizer, where he led the preparation and launch of Pfizer’s COVID-19 vaccine in the United States, including the initial contracts with the U.S. government. He also led Pfizer’s partnership with Gavi, the Vaccine Alliance, which supplies millions of vaccines to the developing world. Before Pfizer, Dave held several roles at Novartis, most notably serving on the front lines of the H1N1 pandemic and leading the Medical Counter Measures group. He holds an M.B.A. from Harvard Business School and a B.S. in Operations Research and Industrial Engineering from Cornell University.